Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, prostate cancer has matured into one of the most multi-mechanism oncology indications globally, anchoring 2,897 active drug programs, 12,474 patent filings since January 2023, and 2,899 ongoing Phase 2 and Phase 3 trials. Notably, the field captures a 200-program sample spanning 125 small molecules, 28 monoclonal antibodies, 9 antibody-drug conjugates, 9 diagnostic radiopharmaceuticals, 8 synthetic peptides, 3 peptide-conjugate radionuclides, and 3 therapeutic radiopharmaceuticals. Specifically, the 2024-2026 wave of approvals…
Author: Eureka LS
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, hypertension has matured into one of the most clinically established generic-dominated cardiovascular indications globally, with 1,669 active drug programs, 5,986 patent filings since January 2023, and 1,781 ongoing Phase 2 and Phase 3 trials. Notably, the field is dominated by small molecule fixed-dose combinations (FDCs) — over 200 sampled programs include 186 small molecule drugs comprising primarily ARB + amlodipine + diuretic + statin combinations. Specifically, the 2023-2026 wave…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, cyclin-Dependent Kinase 2 (CDK2) — the cell cycle kinase increasingly validated as a CDK4/6-inhibitor-resistance target in HR-positive breast cancer — has emerged as one of the most strategically active oncology kinases since 2023, with 227 active drug programs, 388 patent filings since January 2023, and 326 ongoing Phase 2 and Phase 3 trials. Notably, the December 2025 NMPA approval of Culmerciclib represents the first CDK2-selective inhibitor to reach commercial…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, beiGene Ltd. (now operating globally as BeOne Medicines) has consolidated as one of the most clinically active hybrid US/China oncology pharmaceutical companies, anchoring 129 active drug programs and 137 ongoing Phase 2 and Phase 3 trials. Notably, the company spans an unusually broad modality footprint with 48 small molecules, 21 monoclonal antibodies, 12 bispecific T-cell engagers (BiTEs), 11 antibody-drug conjugates (ADCs), 9 PROTACs, 4 bispecific antibodies, 4 trispecific antibodies,…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, idiopathic Pulmonary Fibrosis (IPF) — a progressive interstitial lung disease with a median survival of 3 to 5 years from diagnosis — has finally crossed into a multi-mechanism therapeutic era after a decade dominated by Pirfenidone and Nintedanib. Notably, the field captures 562 active drug programs, 1,538 patent filings since January 2023, and 276 ongoing Phase 2 and Phase 3 trials. The October 2025 FDA approval of Boehringer Ingelheim’s…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, lacosamide (Vimpat) — a third-generation antiepileptic drug developed by UCB and approved by the FDA in August 2008 — has matured into one of the most widely prescribed sodium-channel modulating antiepileptics globally, with multiple regional partners including Daiichi Sankyo (Japan), and 179 ongoing clinical trials extending the molecule into adjacent neurology indications. Notably, the molecule has accumulated 12 patent filings since January 2023 covering generic process improvements and 2…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, astraZeneca Plc has consolidated as one of the world’s most R&D-active integrated pharmaceutical companies, anchoring 1,355 active drug programs and 2,359 ongoing Phase 2 and Phase 3 trials. Notably, the company holds 25+ recently approved products spanning oncology, cardiometabolic, respiratory and immunology, rare disease, and infectious disease — a portfolio breadth approached by only a handful of global peers. Specifically, AstraZeneca’s 2024-2025 commercial momentum has been driven by Brensocatib…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, bevacizumab (Avastin) — a humanized anti-VEGF-A monoclonal antibody originally developed by Genentech and approved by the FDA in February 2004 — has matured into one of the most clinically established and commercially valuable oncology biologics globally. Notably, the molecule remains active in 2,165 ongoing clinical trials, has accumulated 61 patent filings since January 2023 covering follow-on formulations and combinations, and has generated 6 disclosed business development deals over 2022-2025.…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, glioma — including glioblastoma, low-grade astrocytoma, and oligodendroglioma — represents the most clinically challenging neuro-oncology indication, with 2,020 active drug programs, 9,066 patent filings since January 2023, and 1,367 ongoing Phase 2 and Phase 3 trials. Notably, the 2024-2025 wave of approvals — Servier’s Vorasidenib for IDH-mutant low-grade glioma, Day One’s Tovorafenib for BRAF-altered pediatric low-grade glioma, Chimerix’s Dordaviprone for H3 K27M-mutant glioma, and SpringWorks’s Mirdametinib for NF1-related glioma…
Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Moreover, atherosclerosis therapeutics have evolved from statin-dominated lipid-lowering into a multi-mechanism cardiometabolic platform anchoring 691 active drug programs, 4,332 patent filings since January 2023, and 324 ongoing Phase 2 and Phase 3 trials. Notably, the 2024-2026 wave of approvals — Eli Lilly’s Orforglipron oral GLP-1 receptor agonist (April 2026), LIB Therapeutics’s Lerodalcibep PCSK9 mAb (December 2025), and Junshi’s Ongericimab (October 2024) — continues to expand the cardiometabolic toolkit beyond statins,…